-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For reference only by medical professionals
Although currently available biomarkers and risk calculators require further validation, they have shown initial success in improving the early diagnosis of prostate cancer in Chinese men
* The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
.
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.
Although currently available biomarkers and risk calculators require further validation, they have shown initial success in improving the early diagnosis of prostate cancer in Chinese men
J Clin.
[3] Chen WQ, Li H, Sun KX, et al.
China, 2014.
[4] Yu W, Zhou L.
[5] Catalona WJ, Smith DS, Ratliff TL, et al.
[6] Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al.
[7]Summary of safety and effectiveness data: PROGENSA PCA3 assay.
P100033.
[8]Haese A, de la Taille A, Van Poppel H, et al.
[9]Seisen T, Rouprêt M, Brault D, et al.
[10]Ferro M, Bruzzese D, Perdonà S, et al.
[11]Gutierrez A.
[12]Leyten GH, Hessels D, Jannink SA, et al.
[13]Xue L, Mao X, Ren G, et al.
[14]Wu YS, Zhang N, Liu SH, et al.
The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study.
Asian J Androl.
2016; 18(6): 925-9.
[15]Wang Q, Li YF, Jiang J, Zhang Y, Liu XD, Li K.
The establishment and evaluation of a new model for the prediction of prostate cancer.
Medicine (Baltimore).
2017; 96(11): e6138.
[16]Chen R, Xie L, Xue W, et al.
Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
Urol Oncol.
2016; 34(9): 416.
e1,416.
e7.
[17] Niu X, Li J, Das SK, Xiong Y, Yang C, Peng T.
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
BMC Med Imaging.
2017; 17(1): 11.
* The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
.
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.
Click "Read the original text" to see more information~
